Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | PCNA | P12004 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA4 | P22748 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | CASP7 | P55210 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15143431 | 1.00 | MGLL (0.47) | MGLLSMN1; SMN2PCNAGSK3AGSK3B | |
| SCHEMBL16546771 | 1.00 | MGLL (0.47) | MGLLSMN1; SMN2PCNAGSK3AGSK3B | |
| SCHEMBL16329201 | 1.00 | MGLL (0.47) | MGLLSMN1; SMN2PCNAGSK3AGSK3B | |
| SCHEMBL13311292 | 1.00 | MGLL (0.47) | MGLLSMN1; SMN2PCNAGSK3AGSK3B | |
| SCHEMBL13401575 | 1.00 | MGLL (0.47) | MGLLSMN1; SMN2PCNAGSK3AGSK3B | |
| SCHEMBL24591874 | 1.00 | MGLL (0.47) | MGLLSMN1; SMN2PCNAGSK3AGSK3B | |
| SCHEMBL13311294 | 1.00 | MGLL (0.47) | MGLLSMN1; SMN2PCNAGSK3AGSK3B | |
| SCHEMBL16329236 | 1.00 | MGLL (0.47) | MGLLSMN1; SMN2PCNAGSK3AGSK3B | |
| SCHEMBL277453 | 0.97 | SMN1; SMN2 (0.43) | MGLLSMN1; SMN2PCNAGSK3AGSK3B | |
| SCHEMBL24621693 | 0.93 | MGLL (0.55) | MGLLSMN1; SMN2HPGDHTTCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207412-A1 | DIELS-ALDER CONJUGATION METHODS | REGENERON PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240207412-A1 | DIELS-ALDER CONJUGATION METHODS | REGENERON PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-11701427-B2 | Diels-alder conjugation methods | REGENERON PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11701427-B2 | Diels-alder conjugation methods | REGENERON PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11208451-B2 | Protein and protein conjugate for diabetes treatment, and applications thereof | ADDA BIOTECH INC. | 2021-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11208451-B2 | Protein and protein conjugate for diabetes treatment, and applications thereof | GLP1R, GIPR, IAPP | MGLL 2213/4885SMN1; SMN2 2613/4885PCNA 4368/4885 |
| US-20240207412-A1 | DIELS-ALDER CONJUGATION METHODS | GLUL, TGM2, GLS | MGLL 1276/4885SMN1; SMN2 2409/4885PCNA 1661/4885 |
| US-11701427-B2 | Diels-alder conjugation methods | GLUL, TGM2, GLS | MGLL 1276/4885SMN1; SMN2 2409/4885PCNA 1661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.